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A B S T R A C T
Only after the elapse of over half-a-century of warfarin’s reign are we witnessing sig-
nificant progress in anticoagulation therapy with the advent of new anticoagulants 
with predictable pharmacologic profile obviating the need for the routine and burden-
ing coagulation monitoring unlike therapy with vitamin K antagonists. Furthermore, 
these novel agents are devoid of any food interactions and have limited drug-drug 
interactions since they are minimally metabolized via the cytochrome P450. These 
unique pharmacokinetic properties have ushered in a new era in anticoagulation ther-
apy with the continuing development of specific direct factor IIa (thrombin) and factor 
Xa inhibitors. An overview of these novel anticoagulant agents is herein attempted.
Vitamin K antagonists (VKAs) (coumarins), warfarin being the most commonly 
used agent, and acenocoumarol or phenindione available in Greece and other countries, 
despite numerous disadvantages, have essentially been the gold standard and the sole 
form or option of oral anticoagulants available for over half a century, shown to ef-
fectively treat thromboembolism.1,2 Vitamin K antagonists act indirectly to antagonize 
the effect of vitamin K required for the synthesis of active clotting factors II, VII, IX, 
X and anticoagulant proteins C, S and Z, thus reduce the amount of these clotting fac-
tors, thereby producing anticoagulation. Specifically, carboxylation of these coagulation 
factors does not take place because vitamin K is required in this reaction and VKAs 
inhibit regeneration of vitamin K by interfering with vitamin K epoxide reductase. 
However, the use of VKAs has had serious and severe inherent limitations of safety 
and efficacy, significant inter- and intra-patient variability in dose-response, with dose 
titration requiring cumbersome monitoring via laboratory testing of the international 
normalized ratio (INR). These agents have a narrow therapeutic window, a plethora 
of drug and food interactions and unpredictable and variable response also dependent 
on age and/or genetic status and underlying medical conditions.2 These drawbacks have 
compromised patient compliance and have led to under-treatment and difficult anti-
coagulation control, which remains a medical challenge. Several reasons may emerge 
for not taking a VKA, such as patient refusal, patient’s decision to discontinue the 
drug for inconvenience or difficulty in maintaining the INR in the therapeutic range, 
physician’s judgment regarding the inappropriateness of prescribing the drug, or the 
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inability to monitor the INR due to lack of or difficulty in 
accessing a laboratory or lack of family support or assistance 
with this inconvenient process. Until now, patients who are 
not able or willing to take a VKA have had no alternative. 
Only recently, have market competitors begun to emerge with 
the development of new oral anticoagulants, which are direct 
thrombin or active factor Xa inhibitors.3-6
The disadvantages of conventional anticoagulant therapy 
have led investigators to search for the development of new 
alternative agents promising to overcome these drawbacks 
while matching or surpassing the efficacy of VKAs.3-6 Thus, 
a new approach has been investigated of directly targeting a 
single factor to inhibit in the clotting pathway, which is quite 
different from the mechanism of action for VKAs, whereby the 
hepatic synthesis of multiple clotting factors is antagonized. 
Several more specific oral compounds have been developed 
and tested, which achieve their anticoagulant effect by 
stoichiometrically inhibiting a single activated clotting factor, 
either thrombin (factor IIa) or factor Xa (Fig. 1). Reversible 
inhibition is considered important for lowering the bleeding 
risk. These novel agents confer a more predictable and stable 
anticoagulant response, not interfering with diet, and having 
fewer interactions with other drugs. They also provide the 
convenience of oral fixed-dose regimens not requiring the 
tedious monitoring with laboratory testing. All these positive 
attributes may have a favorable impact on patient compliance.
Factor Xa has a strategic role in the coagulation cascade 
(Fig. 1), acting proximal to thrombin at the crossroad of the 
contact activation (intrinsic) and the tissue factor (extrin-
sic) coagulation pathways, which activate the final common 
pathway and lead to the formation of fibrin. Active factor 
Xa hydrolyzes and activates prothrombin to thrombin. 
Thrombin, being the most important part of the coagulation 
cascade, has a broad array of functions, with a primary role 
in the conversion of fibrinogen to fibrin, the scaffolding 
of a hemostatic plug and in thrombin-mediated feedback 
activation of coagulation factors V and VIII.
N o V E l  o R A l  A N T i C o A G U l A N T S
Novel oral agents like the thrombin inhibitor dabigatran 
etexilate and the factor Xa inhibitors rivaroxaban and apixa-
ban, have already become available for prevention of deep 
venous thromboembolism after orthopedic procedures, such 
as elective hip and knee arthroplasty, while other factor Xa 
inhibitors (edoxaban, betrixaban, darexaban) are being evalu-
ated in phase II and III clinical trials.3-20 The initial results of 
the studies employing these new compounds are promising 
and provide evidence of improvement in treatment of venous 
thromboembolism (VTE) and in the prevention of stroke in 
patients with non-valvular atrial fibrillation (AF). In general 
there two separate groups of new oral anticoagulant agents: 
the direct thrombin inhibitors (gatrans) and the direct factor 
Xa inhibitors (xabans).
d A B i G A T R A N
Dabigatran etexilate (Pradaxa®, Boehringer Ingelheim)3-10 
is the prodrug of dabigatran, a non-peptide, reversible oral 
direct thrombin (factor IIa) inhibitor, with a half-life of 12-17 
hours (h). It reaches peak plasma concentration within 0.5-2 h. 
About 80% of the drug is excreted unchanged by the kidneys, 
while the remainder is eliminated via the bile. Cytochrome 
P450 is not involved in the metabolism of the drug and thus 
this new agent has few drug-drug interactions. However, the 
drug is a substrate for the p-glycoprotein (p-GP) system and 
has therefore interactions with amiodarone, clarithromycin 
and verapamil and thus the dose should be decreased in these 
situations. Dabigatran should actually not be co-administered 
with quinidine, a potent p-GP inhibitor. Inducers of p-GP, like 
rifampin, may decrease dabigatran’s availability. Absorption 
of dabigatran is not affected by antacids or histamine 2 block-
ers. Proton pump inhibitors may reduce drug concentration 
slightly but do not produce clinically relevant problems. Food 
containing vitamin K has no effect on the drug action. Galenic 
formulation of the drug with tartaric acid to optimize its ab-
sorption in an acidic milieu accounts for its gastrointestinal 
side effects, mainly dyspepsia. Its stable pharmacokinetics 
and pharmacodynamics allow for a fixed dose administration 
without monitoring of coagulation. Patients with a creatinine 
clearance of 30 - 50 mL/min should receive a lower dose; the 
drug should be avoided in patients with a creatinine clearance 
of <30 mL/min. There is apparently no need to monitor drug 
therapy with use of any laboratory test; however, the drug has 
an inconsistent and dose-dependent effect on ecarin clotting 
time (ECT), thrombin time (TT), INR, and activated partial 
thromboplastin time (aPTT). Todate, there is no known an-
tidote for dabigatran.
Several phase 3 clinical trials have showed comparable 
efficacy of dabigatran with that of enoxaparin in the setting 
of VTE prevention after hip or knee surgery (RE-NOVATE, 
FiGURE 1. Mechanism of action of oral anticoagulants in the 
coagulation cascade. TF = tissue factor; VKA = vitamin K an-
tagonists.
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RE-MODEL, RE-MOBILIZE) or with warfarin for sec-
ondary VTE prevention (RE-COVER, RE-SONATE, RE-
MEDY) and with warfarin for stroke prevention in patients 
with atrial fibrillation (RE-LY) (Table 1).6-10,16-19 The RE-LY 
trial has recently demonstrated that dabigatran is an effective 
alternative for oral anticoagulation with VKAs for stroke 
prevention in >18000 patients with atrial fibrillation.6-10 After 
initial failures with similar medications (e.g. ximelagatran, 
charged with liver dysfunction), these results constitute a 
breakthrough in anticoagulation therapy. In the RE-LY trial,7 
in patients with atrial fibrillation and at least one additional 
risk factor for stroke, after a median follow-up of two years, 
dabigatran 150 mg bid reduced both stroke and intracranial 
and life-threatening hemorrhage more effectively without any 












220 mg qd (VTE)
110 mg bid (AF)
150 mg bid (AF)
RE-NOVATE (VTE), RE-MODEL (VTE), 
RE-MOBILIZE (VTE), RE-COVER (VTE), 
RE-MEDY (VTE), RE-SONATE (VTE), 
RE-DEEM (ACS), RE-LY (AF)
Rivaroxaban** Xarelto® Bayer / Johnson & 
Johnson
Direct factor  
Xa inhibitor
10 mg qd (VTE)
20 mg qd (AF)
RECORD 1-4 (VTE), MAGELLAN (VTE), 
EINSTEIN (VTE), ATLAS TIMI 46 & 51 
(ACS), ROCKET-AF (AF)
Apixaban*** Eliquis® Bristol-Myers 
Squibb/Pfizer
Direct factor  
Xa inhibitor
2.5 mg bid (VTE)
5 mg bid (AF)
APROPOS (VTE), ADVANCE 1-3 
(VTE), ADOPT (VTE), AMPLIFY (VTE), 
APPRAISE (ACS), AVERROES (AF)†, 
ARISTOTLE (AF) ‡
Edoxaban Lixiana® Daiichi Sankyo Direct factor  
Xa inhibitor
30 or 60 mg qd STARS E-3 (VTE), HOKUSAI (VTE), 
ENGAGE AF TIMI-48 (AF)
Betrixaban Portola/Merck Direct factor  
Xa inhibitor
15-40 bid or  
40-80 mg qd
EXPERT (VTE), EXPLORE Xa (AF)
Darexaban 
(YM-150)
Astellas Direct factor  
Xa inhibitor
30 or 60 mg  
qd/bid




Takeda Direct factor  
Xa inhibitor
40-80 mg bid Phase II trial (VTE)
Eribaxaban 
(PD0348292)
Pfizer Direct factor  
Xa inhibitor
0.1-2.5 mg qd Phase II trial (VTE)
LY517717 Eli Lilly Direct factor  
Xa inhibitor
25-150 mg qd Phase II trial (VTE)
AZD0837 Astra Zeneca Direct thrombin 
inhibitor
300 mg qd Phase II trial (VTE)
Sofigatran 
(MCC 977)
Mitsubishi Pharma Direct thrombin 
inhibitor





VKA 6-29 mg qd EmbraceAC (AF/VTE, etc)
ACS=acute coronary syndrome; AF=atrial fibrillation; VTE=venous thromboembolism
*Approved in Canada and by the European Medicines Agency (EMA) for VTE prevention after orthopedic surgery. Also approved in the USA 
(by the FDA on 19/10/2010), in Canada and 12 other countries (EMA approval pending) for stroke prevention for patients with non-valvular atrial 
fibrillation.
**Approved in >110 countries, including the EU and Canada, and most recently (1/7/2011) by the FDA (USA) for VTE prevention after orthopedic 
surgery
***Approved by the European Medicines Agency (EMA) for VTE prevention after orthopedic surgery
†apixaban vs aspirin, ‡apixaban vs coumadin
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significant increase in overall major hemorrhages compared 
with warfarin, whereas the lower dose of dabigatran (110 mg 
bid) while non-inferior at reducing risk of stroke, it reduced 
intracranial, life-threatening, and major bleeding. Dyspepsia 
was a more frequent side-effect of dabigatran (11-12%) com-
pared with warfarin (~6%). Importantly, dabigatran did not 
cause hepatotoxicity. However, a word of caution relates to 
the occurrence of bleeding while receiving dabigatran (there 
was a higher rate of gastrointestinal bleeding with dabigatran 
at the 150-mg dose than with warfarin), as there is no specific 
antidote for this drug, which has a half-life of 12-17 hours. Sup-
portive therapy for severe bleeding may include transfusions 
of fresh-frozen plasma, packed red blood cells, or exploratory 
surgery if indicated.
The American Food & Drug Administration (FDA) ap-
proved dabigatran on October 19, 2010 for anticoagulant use in 
patients with nonvalvular AF.20 However, only the higher dose 
(150 mg bid) was approved for patients with a creatinine clear-
ance >30 mL/min. In patients with severe renal insufficiency 
(creatinine clearance 15 to 30 mL/min) half the dose (75 mg 
bid) was recommended, which however was not evaluated in 
the RE-LY trial. For the same indication, dabigatran has also 
been approved in Canada and at least 12 other countries and 
awaits approval by the European Medicines Agency (EMA). 
Dabigatran is the first new oral anticoagulant to become 
available for clinical use in over half a century. Dabigatran 
has also been approved in Canada and by the EMA for VTE 
prevention after orthopedic surgery.
Other novel oral anticoagulant agents which have received 
or are next in line to receive approval for marketing for venous 
thromboembolism and stroke prevention in patients with VTE 
or AF include the factor Xa inhibitors, rivaroxaban, apixaban, 
edoxaban, betrixaban and darexaban (Table 1).11-20
R i VA R o x A B A N
Rivaroxaban (Xarelto®, Bayer/Johnson & Johnson),17-20 
an oral direct factor Xa inhibitor, is an oxazolidinone deriva-
tive, has a half-life of up to 12 h in the elderly, and up to 9 
h at steady state in healthy young subjects. It reaches peak 
plasma concentration within 2-4 h. Two thirds of the drug are 
metabolized; two thirds are eliminated renally. Rivaroxaban is 
metabolized in the liver involving cytochrome P450 (CYP3A4, 
CYP2J2). It affects prothrombin time more than aPTT and it 
can be monitored by anti-factor-Xa assays if desired.
Rivaroxaban has been approved in Canada and by the 
EMA and most recently by the FDA for VTE prevention 
after orthopedic surgery. In the RECORD trials, the drug 
prevented venous thromboembolism in the orthopedic surgical 
setting significantly better than enoxaparin, with no increased 
bleeding risk. The EINSTEIN trial11 included 3449 patients 
with acute deep vein thrombosis; 1731 were given rivaroxaban 
(15 mg bid for 3 weeks, followed by 20 mg qd) and 1718 were 
given enoxaparin plus a VKA. The primary efficacy outcome 
was recurrent venous thromboembolism. Rivaroxaban had 
non-inferior efficacy with respect to the primary outcome 
(36 events [2.1%], vs 51 events with enoxaparin–vitamin K 
antagonist [3.0%]; hazard ratio, 0.68; P<0.001). The principal 
safety outcome (bleeding) occurred in 8.1% of the patients in 
each group. In the continued-treatment study (EINSTEIN-
Extension), which included 602 patients in the rivaroxaban 
group and 594 in the placebo group, rivaroxaban had superior 
efficacy (8 events [1.3%], vs 42 with placebo [7.1%]; hazard 
ratio, 0.18; P<0.001). Four patients in the rivaroxaban group 
had nonfatal major bleeding (0.7%), versus none in the placebo 
group (P = 0.11).
Rivaroxaban was also assessed in the ROCKET-AF trial 
in 14264 patients with AF and found to be non-inferior to 
warfarin.13 Rivaroxaban was given at a dose of 20 mg qd (or 
15 mg qd in patients with renal impairment). The primary end 
point was a composite of stroke and non-cerebral embolism; 
rivaroxaban was found to be superior to warfarin by 21% with 
regards to the primary endpoint in patients who remained on 
treatment over the course of the 40-month trial; it was not 
superior to warfarin in the stricter intention-to-treat analysis. 
In terms of bleeding, the rates of the composite major and 
non-major clinically relevant bleeding were comparable in 
the rivaroxaban- and warfarin-treatment arms, with less fatal 
bleeding and intracranial hemorrhage observed among those 
treated with the new drug. Major bleeding occurred in 395 
patients, at a rate of 3.60 per 100 patient-years, in the warfarin-
treated patients, and in 386 patients, or at a rate of 3.45 per 100 
patient-years, in the rivaroxaban-treated patients (p=0.576).
A p i x A B A N
Apixaban (Eliquis®, Pfizer/Bristol-Myers Squibb),17-20 a 
direct Xa inhibitor, has a half-life of 8-15 h and reaches peak 
plasma concentration within 1-4 h. It was evaluated in the 
AVERROES trial12 against aspirin in 5599 patients with AF for 
whom VKA therapy was unsuitable and found to be superior to 
aspirin with fewer cases of stroke or systemic embolism (1.6% 
per year vs 3.7% per year; hazard ratio 0.45; p<0.001) without 
significantly increasing the risk of major bleeding or intracra-
nial hemorrhage.12 The incidence of major bleeding was 1.4% 
per year in the apixaban group and 1.2% in the aspirin group 
(p=0.57). The full results of the ARISTOTLE trial compar-
ing apixaban (5 mg bid) with warfarin in over 18000 patients 
with atrial fibrillation are still pending;15 a preliminary press 
release indicates that apixaban was non-inferior to warfarin, 
and that apixaban “also met the key secondary end-points of 
superiority on efficacy and on major bleeding compared with 
warfarin.”15 Apixaban just recently received approval for use 
in the 27 countries of the European Union for the prevention 
of venous thromboembolic (VTE) events in patients who have 
undergone elective hip- or knee-replacement surgery.
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Edoxaban (Lixiana®, Daiichi Sankyo) has a short half-life 
of 8–10 hours, and is mainly eliminated via the kidneys. The 
ENGAGE AF TIMI-48 trial compares two doses of edoxa-
ban (30 and 60 mg once daily) with INR-adjusted warfarin 
for stroke prevention in patients with AF. Enrolment has 
been completed with 21 107 patients, and trial completion is 
scheduled for mid-2012. Betrixaban (Portola/Merck) has a 
bioavailability of 47%, a half-life of 19 h and is excreted almost 
unchanged in bile. A completed phase II, randomized, open-
label VTE prevention trial (EXPERT) in patients undergoing 
total knee replacement provided evidence for the efficacy and 
safety of betrixaban (15 or 40 mg bid) compared with enoxapa-
rin (30 mg bid) in 215 patients. darexaban (YM-150, Astellas) 
is another direct factor Xa inhibitor, being evaluated in VTE, 
acute coronary syndromes (ACS) and AF patients in phase II 
and III trials. Preliminary results report a favorable efficacy 
and safety profile of the drug in comparison with enoxaparin 
in patients with VTE, and a promising safety profile in com-
parison with warfarin in patients with AF. Important potential 
advantages over other similar drugs are claimed regarding 
its lack of cytochrome P3A4 inhibition and hence drug-drug 
interactions and its better gastrointestinal tolerability.
AZd-0837 (AstraZeneca) is a prodrug and another re-
versible direct thrombin inhibitor. This agent is similar to 
ximelagatran apparently without the associated liver toxicity. 
Its half-life is 9 hours. It is metabolized by cytochrome 2C9, 
2C19, and 3A4. AZD-0837 is eliminated by both renal and 
hepatic pathways. Preliminary data from 2 studies in 955 
and 250 patients respectively with AF indicated a similar or 
lower incidence of bleeding than warfarin, however the drug 
produced a higher incidence of dyspepsia compared with war-
farin leading to more frequent discontinuation of treatment. 
Although not powered to detect any significant differences, 
the studies indicated a low incidence of stroke or VTE among 
all groups.20
Sofigatran (MCC 977, Mitsubishi Pharma) is also a direct 
thrombin inhibitor which is in phase II clinical trials for treat-
ment of deep vein thrombosis. TTp889 (Transtech Pharma) is 
a novel anticoagulant agent, a factor IXa (reversible) inhibi-
tor, first used in a phase II clinical trial for VTE, but in the 
dose employed the drug was ineffective. Finally, Tecarfarin 
(ATI-5923, ARYx Therapeutics)23 is a new oral VKA, which, 
unlike warfarin, is not metabolized via the cytochrome P450 
(designed to be metabolized through the esterase pathway), 
thus avoiding several potential drug-drug interactions. The 
agent is compared with warfarin in phase II/III trials in patients 
with AF and other groups requiring anticoagulation.23
l i M i T A T i o N S
The shorter half-life of these new agents will probably 
improve their safety profile and obviate the need for pre-
operative anticoagulation “bridging”, but, on the other hand, 
it will also pose a risk of inferior protection if doses are missed. 
Some of these new drugs are substrates for P-glycoprotein 
and they are metabolized by cytochrome P-450 3A4.19 Hence, 
caution is advised to avoid the concomitant use of drugs that 
inhibit these pathways, such as azole antifungal agents or 
protease inhibitors. Other limitations of these new drugs may 
relate to gastrointestinal side effects, mode of metabolism and 
route of elimination. Also specific antidotes are not available 
for any of them, albeit their short half-life may prove advanta-
geous in this regard. Finally, the cost issue is very important, 
as the cost of these new agents will be much higher than that 
of VKAs, and needs to be factored into the decision-making 
process with any of the new anticoagulants.
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